Spots Global Cancer Trial Database for A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors
Official Title: A Phase 1, Uncontrolled, Open-label, Non-randomized, Dose-escalation Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors, Followed by an Uncontrolled, Randomized Study in Patients With Esophageal Cancer or Head and Neck Squamous Cell Carcinoma
Study ID: NCT06248411
Conditions
Study Description
Brief Summary: This is the first in human study of KK2260. In Part 1, the maximum tolerated dose (MTD) will be determined while evaluating the safety and tolerability of KK2260 in patients with advanced or metastatic solid tumors (any cancer type). Part 2 will compare the safety and tolerability of KK2260 in patients with multiple cancer types in multiple dose regimen arms.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
National Cancer Center Hospital East, Kashiwa city, Chiba, Japan
National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
